142P Early-phase clinical trials in gynaecologic malignancies: A 13-year single-center experience

V. Ricco; M. Imbimbo; M. Pedrani; A. Gagliano; M. NERONE; E.A. Ciliberti; A.P.A. Badellino; N. Scahett; H-M. Lin; L. Tortola; D. Coppola; E. Bisdomini; A.R. Carvalho Mendonca; A. Fossati; M. Iannace; L. Pallavicini; C. Cafaro Greco; A. Stathis; C. Sessa; I. Colombo

doi:10.1016/j.esmoop.2026.108189

Key Points

To assess outcomes of patients with advanced gynaecologic malignancies enrolled in phase I trials over 13 years.
Retrospective evaluation of patients with advanced gynaecologic cancers
Analysis of results from phase I trials at a single academic center
Duration of evaluation spans 13 years.
Patients exhibited clinical benefit from innovative agents in early-phase trials.
The study highlights the potential effectiveness of phase I trials in heavily pretreated populations.

Implication

Retrospective evaluation of outcomes in advanced gynaecologic cancers, highlighting clinical benefits of phase I trials.

Abstract

Patients (pts) with advanced gynaecologic cancers often progress after standard therapies. Phase I trials provide access to innovative agents and may offer clinical benefit in heavily pretreated populations. We retrospectively evaluated outcomes of pts enrolled in phase I trials at a single academic center over 13 years.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ricco et al. (2026) studied this question.

synapsesocial.com/papers/6a48a6b689561a0c2d78e9c5 https://doi.org/10.1016/j.esmoop.2026.108189

View Full Paper

Ask AI

Bookmark

Share

142P Early-phase clinical trials in gynaecologic malignancies: A 13-year single-center experience

Key Points

Implication

Abstract

Discussion

Cite This Study

142P Early-phase clinical trials in gynaecologic malignancies: A 13-year single-center experience

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading